Search details
1.
Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept.
Ann Surg Oncol
; 31(2): 957-965, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37947974
2.
Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
Breast Cancer Res Treat
; 201(2): 215-225, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37355526
3.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 625-635, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35405088
4.
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Breast Cancer Res
; 24(1): 58, 2022 09 02.
Article
in English
| MEDLINE | ID: mdl-36056374
5.
A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients.
Ann Surg
; 276(5): e553-e562, 2022 11 01.
Article
in English
| MEDLINE | ID: mdl-33156057
6.
Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03.
Ann Surg
; 275(3): 576-581, 2022 03 01.
Article
in English
| MEDLINE | ID: mdl-32657944
7.
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel.
Oncologist
; 27(9): 722-731, 2022 09 02.
Article
in English
| MEDLINE | ID: mdl-35704278
8.
ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer.
Mod Pathol
; 35(12): 1804-1811, 2022 12.
Article
in English
| MEDLINE | ID: mdl-35842479
9.
Ten years of live surgical broadcast at Charité-MAYO conferences (2010-2019): a systematic evaluation of the surgical outcome.
Int J Gynecol Cancer
; 32(6): 746-752, 2022 06 06.
Article
in English
| MEDLINE | ID: mdl-35383091
10.
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Breast Cancer Res Treat
; 187(2): 467-476, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-33748921
11.
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Int J Cancer
; 146(1): 262-271, 2020 01 01.
Article
in English
| MEDLINE | ID: mdl-31162838
12.
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
Cancer
; 126(22): 4847-4858, 2020 11 15.
Article
in English
| MEDLINE | ID: mdl-32780421
13.
Perception of side effects associated with anticancer treatment in women with breast or ovarian cancer (KEM-GO-1): a prospective trial.
Support Care Cancer
; 28(8): 3605-3615, 2020 Aug.
Article
in English
| MEDLINE | ID: mdl-31828488
14.
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.
Int J Cancer
; 145(8): 2114-2121, 2019 10 15.
Article
in English
| MEDLINE | ID: mdl-30901076
15.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 175(1): 265-266, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30632020
16.
ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment-A New Concept.
Ann Surg Oncol
; 31(2): 1033-1034, 2024 02.
Article
in English
| MEDLINE | ID: mdl-38093166
17.
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Lancet Oncol
; 19(7): 904-915, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29804902
18.
RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial.
BMC Cancer
; 18(1): 851, 2018 Aug 25.
Article
in English
| MEDLINE | ID: mdl-30144818
19.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 165(3): 573-583, 2017 Oct.
Article
in English
| MEDLINE | ID: mdl-28664507
20.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
Lancet Oncol
; 15(10): 1137-46, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-25130998